The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

Oncogene

Volumn 34, Issue 2, 2015, Pages 199-208

  Hayashi, H ^a   Arao, T ^a   Togashi, Y ^a   Kato, H ^a   Fujita, Y ^a   De Velasco, M A ^a   Kimura, H ^a   Matsumoto, K ^a   Tanaka, K ^a   Okamoto, I ^a   Ito, A ^a   Yamada, Y ^b   Nakagawa, K ^a   Nishio, K ^a  

^a KINKI UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

gastric cancer; gene amplification; OCT4; POU5F1B; pseudogene

Indexed keywords

MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PROGNOSIS; PSEUDOGENE; STOMACH TUMOR; XENOGRAFT;

ANIMALS; CELL PROLIFERATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HEK293 CELLS; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OCTAMER TRANSCRIPTION FACTOR-3; PHENOTYPE; PROGNOSIS; PSEUDOGENES; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84890473944     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.547     Document Type: Article

References (39)

1. Scholer HR, Ruppert S, Suzuki N, Chowdhury K, Gruss P. New type of POU domain in germ line-specific protein Oct-4. Nature 1990; 344: 435-439.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
3. Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, Andrews PW. OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells 2008; 26: 3068-3074.
4. Cauffman G, Liebaers I, Van Steirteghem A, Van de Velde H. POU5F1 isoforms show different expression patterns in human embryonic stem cells and preimplantation embryos. Stem Cells 2006; 24: 2685-2691.
5. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007; 120: 1598-1602.
6. Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 2001; 20: 8085-8091.
7. Wu CL, Shieh GS, Chang CC, Yo YT, Su CH, Chang MY et al. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res 2008; 14: 1228-1238.
8. Pink RC, Wicks K, Caley DP, Punch EK, Jacobs L, Carter DR. Pseudogenes: pseudo-functional or key regulators in health and disease? RNA 2011; 17: 792-798.
9. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X et al. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell 2012; 149: 1622-1634.
10. Liedtke S, Enczmann J, Waclawczyk S, Wernet P, Kogler G. Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 2007; 1: 364-366.
11. Suo G, Han J, Wang X, Zhang J, Zhao Y, Dai J. Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun 2005; 337: 1047-1051.
12. Panagopoulos I, Moller E, Collin A, Mertens F. The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1 isoform 1. Oncol Rep 2008; 20: 1029-1033.
13. Zhao S, Yuan Q, Hao H, Guo Y, Liu S, Zhang Y et al. Expression of OCT4 pseudogenes in human tumours: lessons from glioma and breast carcinoma. J Pathol 2011; 223: 672-682.
14. Kastler S, Honold L, Luedeke M, Kuefer R, Moller P, Hoegel J et al. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. Prostate 70: 666-674.
15. Furuta K, Arao T, Sakai K, Kimura H, Nagai T, Tamura D et al. Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells. Cancer Sci 2012; 103: 221-227.
16. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009; 383: 157-162.
17. Cantz T, Key G, Bleidissel M, Gentile L, Han DW, Brenne A et al. Absence of OCT4 expression in somatic tumor cell lines. Stem Cells 2008; 26: 692-697.
18. Wang X, Dai J. Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. Stem Cells 2010; 28: 885-893.
19. Pain D, Chirn GW, Strassel C, Kemp DM. Multiple retropseudogenes from pluripotent cell-specific gene expression indicates a potential signature for novel gene identification. J Biol Chem 2005; 280: 6265-6268.
20. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574-577.
21. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol 2008; 14: 5962-5968.
22. Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A et al. Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 702-705.
23. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-637.
24. Haiman CA, Le Marchand L, Yamamato J, Stram DO, Sheng X, Kolonel LN et al. A common genetic risk factor for colorectal and prostate cancer. Nat Genet 2007; 39: 954-956.
25. Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007; 67: 2951-2956.
26. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-649.
27. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007; 39: 989-994.
28. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-658.
29. Bier A, Oviedo-Landaverde I, Zhao J, Mamane Y, Kandouz M, Batist G. Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target. Mol Cancer Ther 2009; 8: 786-793.
30. Yu H, Zhao X, Su B, Li D, Xu Y, Luo S et al. Expression of NF1 pseudogenes. Hum Mutat 2005; 26: 487-488.
31. Zhang J, Wang X, Li M, Han J, Chen B, Wang B et al. NANOGP8 is a retrogene expressed in cancers. FEBS J 2006; 273: 1723-1730.
32. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A codingindependent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033-1038.
33. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012; 106: 727-732.
34. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011; 29: 4789-4795.
35. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008; 22: 2226-2229.
36. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res 2010; 70: 2053-2063.
37. Tanaka K, Arao T, Maegawa M, Matsumoto K, Kaneda H, Kudo K et al. SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. Int J Cancer 2009; 124: 1072-1080.
38. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007; 13: 3051-3057.
39. Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 2008; 99: 2193-2199.